Small intestinal bacterial overgrowth (SIBO) happens when overall bacterial population increases abnormally in the small intestine—especially types of bacteria not commonly found in that part of the digestive tract. Once they reside in the small intestine, they can cause numerous symptoms because they ferment foods like fibres and sugars, which would normally occur in the large intestine. The process of fermentation leads to hydrogen, methane, or hydrogen sulfide gasses released in the small intestine, which may be a cause of symptoms like swelling, pain, dyspepsia, decreased colon motility (constipation), or increased osmotic flow into the colon (diarrhea). Typically, hydrogenic and hydrogen-sulfide SIBO are correlated with loose stools/diarrhea, whereas methagenic SIBO is correlated with constipation.1 SIBO may be the underlying dysfunction of many digestive concerns, especially in people diagnosed with irritable bowel syndrome (IBS), as it is hypothesized that between 7% and 78% of people with IBS suffer from SIBO and, therefore, it is no longer a psychiatric-induced disorder.2
What Are SIBO Symptoms?
SIBO symptoms can include abdominal bloating and/or discomfort/pain after meals; excessive burping and/or gas; nausea; heartburn/gastroesophageal reflux disease (GERD), sensation of fullness and slow digestion; chronic loose stools and/or constipation; alternating loose stools and constipation; urgent bowel movements; steatorrhea (excess fat in feces), halitosis (bad breath) and/or bad taste in the mouth; skin issues like acne, rosacea3, fatigue, weight loss, and iron and/or vitamin B12 deficiencies4; or any combination of the above. The bacteria use both iron and B12 for their own metabolism, which may induce a functional deficiency of bioavailable iron and B12 in the body.5 SIBO can be suspected in cases where there is no clear explanation of iron deficiency anemia>6 or megaloblastic anemia.7 SIBO may also be suspected if the low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet is helpful or if eating a high-fibre diet aggravates intestinal symptoms. SIBO can be presumed if it is difficult to pinpoint which foods are aggravating symptoms through dietary restriction and if probiotics taken alone seem to provoke symptoms rather than improve them. There are indeed some foods that do tend to aggravate intestinal symptoms when SIBO is present, and these are garlic, onions, apples, pears, apricots, mangos, peaches, plums, cauliflower, broccoli, asparagus, cabbage, beans, lentils, and legumes.
The Underlying Cause
What is unique to SIBO, compared to other gastrointestinal (GI) disorders, is the dysfunction of the nerve-intestinal motility symptom in the body called the migrating motor complex (MMC).8 The MMC, when properly functioning, moves digested food from the small intestine to the large intestine. There is a possible association with acute viral gastroenteritis and the onset of IBS symptoms like chronic diarrhea, chronic constipation, and GERD.9,10,11 The acute infectious illness is one way which the MMC may weaken12, and factors associated with decreased MMC are long-standing diabetes or connective tissue disorder. In a study following a waterborne viral gastroenteritis (GE) outbreak, it has been shown that norovirus GE leads to the development of postinfectious IBS in a substantial proportion of patients (13%) 13, thus potentially leading to SIBO. When there is a dysfunctional MMC, the food is slower to move out of the small intestine, so there is inefficient sweeping of bacteria out of the small intestines to the large intestine.
There can be other causes in the development of SIBO, and these include hypochlorhydria or chronic antacid medication use14, bile insufficiency,15,16 traumatic brain injury17, intestinal strictures/adhesions18, ileocecal valve dysfunction19, bowel surgery, celiac disease, gastroparesis (due to diabetes), and inflammatory bowel disease20, or any disorder which causes either accumulation of bacteria in the small intestine through inefficient sweeping or retrograde from the large intestine.
There is a myriad of conditions associated with SIBO: intestinal permeability21, nonalcoholic fatty liver disease (NAFLD),22,23 interstitial cystitis24, hypothyroidism25, restless-legs syndrome26, histamine intolerance27, gall-bladder removal28, autoimmune conditions, Crohn’s disease29, ulcerative colitis30, systemic sclerosis31,32. Research has shown that NAFLD is correlated with increased intestinal permeability as well as higher prevalence of SIBO33. Furthermore, nonalcoholic steatohepatitis (NASH) is also found to be significantly correlated with SIBO.34 These findings, however, suggest correlation and not causation, and may be closely interlinked.
If SIBO is suspected, the SIBO breath test is a popular, noninvasive method. While research is still determining what is the most sensitive test, substrates that are used for the test often provide false positive results, and individual variation in intestinal transit time may also create both false negatives or positives.35 Compared to the gold standard of upper-gut aspirate, breath tests have high specificity but very low sensitivity.36 However, with proper guidance, the breath test can be helpful. If positive, then appropriate administration of an eradication treatment is utilized based on the results. Once the overgrowth is treated, digestive and associated symptoms are likely to resolve, and the digestive tract can then be taken care of with a recovery protocol using lifestyle and nutrition modification as well as plants and nutraceuticals.
What Is the SIBO Breath Test, and What Can You Expect?
The SIBO breath test includes a prep diet the day before testing to limit the chances of certain foods interfering with test results. SIBO bacteria feed mostly on sugars and plant products, so, according to the SIBO Centre for Digestive Health, the only foods to eat during the prep diet are:37
- Any meat, poultry, fish, or seafood that is not cured or brined
- Plain, steamed white rice
- Eggs
- Clear meat broth (made only from the meat; no bone, cartilage, or vegetables)
- Fats/oils (coconut/olive/vegetable oils, butter, or lard)
- Salt and pepper (no other herbs/spices)
- Weak black coffee and/or weak black tea (plain, no sweeteners or cream, no green or herbal teas)
- Plain water (no mineral water or water with additives)
It is also recommended to do an overnight fast, and then a baseline breath sample is collected. The day of the testing, a solution is taken (typically lactulose), and breath samples are collected over the next three hours to assess hydrogen and methane production from the small intestine bacteria present.38 If there is a rise in gasses, then this would be considered a positive result. Hydrogen and methane are the two main gasses that the SIBO breath test can detect. Newer breath tests can also detect hydrogen-sulfide gasses.39,40,41
What to Do Following a Positive Test
There are two phases of SIBO treatment, which include the antimicrobial or eradication phase and the recovery phase, which includes digestive healing and prevention of SIBO recurrence.
First Step: The Eradication Phase
Treatment is dependent on which gasses were considered in the unhealthy range and would include two to four weeks of one or more of antimicrobials, which may include antibiotics (neomycine or rifamaxin)42,43,44,45 antimicrobial herbs (goldenseal, myrrh, thyme, garlic, oregano, berberine, uva ursi, and silver hydrosol),46,47 or, if nonresponsive to those, agents which are biofilm disruptors (if this is new to you, biofilm disruptors remove the protective coating on the bacteria we want to eradicate!). Biofilm disruptor examples include bismuth subnitrate, DMPS and alpha-lipoic acid, N‑acetylcysteine, and black cumin seed oil.48,49 Other considerations for a holistic success include agents that support the detoxification pathways of the liver, to quench things like free radicals. These include milk thistle, turmeric, dandelion, artichoke, alpha‑lipoic acid, Schizandra chinensis herb, and N‑acetylcysteine. In practice, as a naturopath, it appears that the combination of antibiotics such as rifaximin and an herbal antimicrobial, possibly due to the other effects of plant medicines, are the most helpful for SIBO eradication.
Lactobacillus casei probiotic, with antibiotic treatment, have been demonstrated in one small study to be more effective than antibiotics alone for symptoms’ alleviation.50 Saccharomyces boulardii probiotics may also be considered in individuals with short-bowel syndrome,51 but was not found to be effective in patients with IBS.
Eradication typically takes two to four weeks of treatment; however, biofilm agents may be used beforehand. As an alternative to antimicrobials, the elemental diet—which is a combination of amino acids, specific sugars, fats, vitamins, and minerals—can be utilized for periods of 14 to 21 days. The elemental diet is the only science-based diet to date that is potentially effective in reversing SIBO.52 However, this diet includes no solid foods, making it extremely difficult—and potentially harmful in certain vulnerable populations.
Second Step: The Recovery Phase
A simple suggestion for SIBO, to prevent its recurrence, is to space meals 2½–3 hours apart. This is the ideal time for the MMC to be able to complete its full contraction and sweep any bacteria from the small to the large intestine. As well, during treatment, fermented foods like kimchi, sauerkraut, kombucha, yogurt, miso, etc. should all be avoided so not to further feed the overgrowth of even beneficial bacteria in the small intestine!
Other gut healing supplements, if necessary, include L‑glutamine, zinc carnosine, N‑acetylglucosamine, and omega‑3s. Prokinetics (a type of drugs which enhance gastrointestinal motility), like a pharmaceutical called prucalopride53, or natural treatments like 5‑hydroxytryptophane (5‑HTP) or ginger may be suggested to strengthen the MMC. Other pharmaceutical prokinetics include low-dose erythromycin54 and low dose naltrexone, which is especially beneficial in those with autoimmunity. It is also crucial to support in case of gastric hypochlorhydria (which lowers the antibacterial function of the stomach) and/or lower-esophageal dysfunction, which can be done utilizing betaine hydrochloride, herbal bitters like gentian, or D‑limonene (also a mild prokinetic). Specific treatment recommendations are best discussed with your health-care provider, naturopathic doctor, or family physician.
Conclusion
SIBO is an increasingly common cause of digestive issues and, as mentioned, it can exacerbate many associated symptoms and health problems. It is imperative to eradicate the overgrowth, heal the digestive tract, and prevent SIBO recurrence for optimal health.
Références
- Singer‑Englar, T., A. Rezaie, K. Gupta, N. Pichetshote, R. Sedighi, E. Lin, K.S. Chua, and M. Pimentel. “Validation of a 4-gas device for breath testing in the determination of small intestinal bacterial overgrowth.” Gastroenterology, Vol. 154, No. 6, Suppl. 1 (2018): S‑281, Sa1219.
- Ghoshal, U.C., R. Shukla, and U. Ghoshal. “Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy.” Gut Liver, Vol. 11, No. 2 (2017): 196–208.
- Daou, H., M. Paradiso, K. Hennessy, and L. Seminario‑Vidal. “Rosacea and the microbiome: A systematic review.” Dermatology and Therapy, Vol. 11, No. 1 (2021): 1–12.
- Bures, J., J. Cyrany, D. Kohoutova, M. Förstl, S. Rejchrt, J. Kvetina, V. Vorisek, and M. Kopacova. “Small intestinal bacterial overgrowth syndrome.” World Journal of Gastroenterology, Vol. 16, No. 24 (2010): 2978–2990.
- Dukowicz, A.C., B.E. Lacy, and G.M. Levine. “Small intestinal bacterial overgrowth: A comprehensive review.” Gastroenterology & Hepatology, Vol. 3, No. 2 (2007): 112–122.
- Murphy, M.F., N.A. Sourial, J.F. Burman, D.V. Doyle, S. Tabaqchali, and D.L. Mollin. “Megaloblastic anaemia due to vitamin B12 deficiency caused by small intestinal bacterial overgrowth: Possible role of vitamin B12 analogues.” British Journal of Haematology, Vol. 62, No. 1 (1986): 7–12.
- Losurdo, G., F. Salvatore D’Abramo, G. Indellicati, C. Lillo, E. Ierardi, and A. Di Leo. “The influence of small intestinal bacterial overgrowth in digestive and extra-intestinal disorders.” International Journal of Molecular Sciences, Vol. 21, No. 10 (2020): 3531.
- Pimentel, M., E.E. Soffer, E.J. Chow, Y. Kong, and H.C. Lin. “Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth.” Digestive Diseases and Sciences, Vol. 47, No. 12 (2002): 2639–2643.
- Porter, C.K., D. Choi, B. Cash, M. Pimentel, J. Murray, L. May, and M.S. Riddle. “Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness.” BMC Gastroenterology, Vol. 13 (2013): 46.
- Riddle, M.S., H.L. DuPont, and B.A. Connor. “ACG clinical guideline: Diagnosis, treatment, and prevention of acute diarrheal infections in adults.” The American Journal of Gastroenterology, Vol. 111, No. 5 (2016): 602–622.
- Riddle, M.S., M. Welsh, C.K. Porter, C. Nieh, E.J. Boyko, G. Gackstetter, and T.I. Hooper. “The epidemiology of irritable bowel syndrome in the US military: Findings from the Millennium Cohort Study.” The American Journal of Gastroenterology, Vol. 111, No. 1 (2016): 93–104.
- Parkman, H.P., W.L. Hasler, and R.S. Fisher. “American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis.” Gastroenterology, Vol. 127, No. 5 (2004): 1592–1622
- Zanini, B., C. Ricci, F. Bandera, F. Caselani, A. Magni, A.M. Laronga, and A. Lanzini; San Felice del Benaco Study Investigators. “Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak.” The American Journal of Gastroenterology, Vol. 107, No. 6 (2012): 891–899.
- Urita, Y., M. Sugimoto, K. Hike, N. Torii, Y. Kikuchi, H. Kurakata, E. Kanda, M. Sasajima, and K. Miki. “High incidence of fermentation in the digestive tract in patients with reflux oesophagitis.” European Journal of Gastroenterology & Hepatology, Vol. 18, No. 5 (2006): 531–535.
- Urdaneta, V., and J. Casadesús. “Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts.” Frontiers in Medicine, Vol. 4 (2017): 163.
- Gupta, A., R.K. Dhiman, S. Kumari, S. Rana, R. Agarwal, A. Duseja, and Y. Chawla. “Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.” Journal of Hepatology, Vol. 53, No. 5 (2010): 849–855.
- Olsen, A.B., R.A. Hetz, H. Xue, K.R. Aroom, D. Bhattarai, E. Johnson, S. Bedi, C.S. Cox Jr, and K. Uray. “Effects of traumatic brain injury on intestinal contractility.” Neurogastroenterology and Motility, Vol. 25, No. 7 (2013): 593‑e463.
- Dukowicz, Lacy, and Levine. “Small intestinal bacterial overgrowth.”
- Roland, B.C., M.M. Ciarleglio, J.O. Clarke, J.R. Semler, E. Tomakin, G.E. Mullin, and P.J. Pasricha. “Low ileocecal valve pressure is significantly associated with small intestinal bacterial overgrowth (SIBO).” Digestive Diseases and Sciences, Vol. 59, No. 6 (2014): 1269–1277.
- Dukowicz, Lacy, and Levine. “Small intestinal bacterial overgrowth.”
- Park, J.H., D.I. Park, H.J. Kim, Y.K. Cho, C.I. Sohn, W.K. Jeon, B.I. Kim, K.H. Won, and S.M. Park. “The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome.” Gut and Liver, Vol. 3, No. 3 (2009): 174–179.
- Thimme, R., H.C. Spangenberg, and H.E. Blum. “[Hepatology 2009]” (article in German). Deutsche Medizinische Wochenschrift, Vol. 134, No. 25–26 (2009): 1335–1339.
- Shanab, A.A., P. Scully, O. Crosbie, M. Buckley, L. O’Mahony, F. Shanahan, S. Gazareen, E. Murphy, and E.M. Quigley. “Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8.” Digestive Diseases and Sciences, Vol. 56, No. 5 (2011): 1524–1534.
- Weinstock, L.B., C.G. Klutke, and H.C. Lin. “Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms.” Digestive Diseases and Sciences, Vol. 53, No. 5 (2008): 1246–1251.
- Lauritano, E.C., A.L. Bilotta, M. Gabrielli, E. Scarpellini, A. Lupascu, A. Laginestra, M. Novi, et al. “Association between hypothyroidism and small intestinal bacterial overgrowth.” The Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 11 (2007): 4180–4184.
- Weinstock, L.B., S.E. Fern, and S.P. Duntley. “Restless legs syndrome in patients with irritable bowel syndrome: Response to small intestinal bacterial overgrowth therapy.” Digestive Diseases and Sciences, Vol. 53, No. 5 (2008): 1252–1256.
- Schnedl, W.J., and D. Enko. “Histamine intolerance originates in the gut.” Nutrients, Vol. 13, No. 4 (2021): 1262.
- Sung, H.J., C.‑N.Paik, W.C. Chung, K.‑M. Lee, J.‑M. Yang, and M.‑G. Choi. “Small intestinal bacterial overgrowth diagnosed by glucose hydrogen breath test in post-cholecystectomy patients.” Journal of Neurogastroenterology and Motility, Vol. 21, No. 4 (2015): 545–551.
- Ruback Bertges, E., and J.M. Fonseca Chebli. “Prevalence and factors associated with small intestinal bacterial overgrowth in patients with Crohn’s disease: A retrospective study at a referral center.” Arquivos de Gastroenterologia, Vol. 57, No. 3 (2020): 283–288.
- Yang, C., X. Guo, J. Wang, H. Fan, X. Huo, L. Dong, and Z. Duan. “Relationship between small intestinal bacterial overgrowth and peripheral blood ET, TLR2 and TLR4 in ulcerative colitis.” Journal of the College of Physicians and Surgeons, Vol. 30, No. 3 (2020): 245–249.
- Pittman, N., S.M. Rawn, M. Wang, A. Masetto, K.A. Beattie, and M. Larché. “Treatment of small intestinal bacterial overgrowth in systemic sclerosis: A systematic review.” Rheumatology, Vol. 57, No. 10 (2018): 1802–1811.
- García‑Collinot, G., E.O. Madrigal‑Santillán, M.A. Martínez‑Bencomo, R.A. Carranza‑Muleiro, L.J. Jara, O. Vera‑Lastra, D.H. Montes‑Cortes, G. Medina, and M.P. Cruz‑Domínguez. “Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis.” Digestive Diseases and Sciences, Vol. 65, No. 4 (2020): 1134–1143.
- Thimme, Spangenberg, and Blum. “[Hepatology 2009].”
- Shanab et al. “Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis.”
- Ghoshal, U.C. “How to interpret hydrogen breath tests.” Journal of Neurogastroenterology and Motility, Vol. 17, No. 3 (2011): 312–317.
- Ghoshal, U.C., D. Srivastava, U. Ghoshal, and A. Misra. “Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture.” European Journal of Gastroenterology & Hepatology, Vol. 26, No. 7 (2014): 753–760.
- SIBO Center for Digestive Health. “Prep diet overview: What is the prep diet?” · https://sibocenter.com/prep-diet-overview/ · Accessed 2021‑11‑11.
- Rezaie, A., M. Buresi, A. Lembo, H. Lin, R. McCallum, S. Rao, M. Schmulson, M. Valdovinos, S. Zakko, and M. Pimentel. “Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American consensus.” The American Journal of Gastroenterology, Vol. 112, No. 5 (2017): 775–784.
- Singer-Englar, T et al. “Competitive hydrogen gas utilization by methane- and hydrogen sulfide–producing microorganisms and associated symptoms: Results of a novel 4‑gas breath test machine.” Gastroenterology, Vol. 154, No. 6 (2018): S‑47, #182.
- Pimentel, M., A. Hosseini, C. Chang, R. Mathur, M. Rashid, R. Sedighi, H. Fowler, J. Torosyan, J. Wang, and A. Rezaie. “Exhaled hydrogen sulfide is increased in patients with diarrhea: Results of a novel collection and breath testing device.” Gastroenterology, Vol. 160, No. 6 (2021): S‑278, Fr248.
- Singer‑Englar et al. “Sa1219—Validation of a 4-gas device for breath testing.”
- Low, K., L. Hwang, J. Hua, A. Zhu, W. Morales, and M. Pimentel. “A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.” Journal of Clinical Gastroenterology, Vol. 44, No. 8 (2010): 547–550.
- Pimentel, M., C. Chang, K.S. Chua, J. Mirocha, J. DiBaise, S. Rao, and M. Amichai. “Antibiotic treatment of constipation-predominant irritable bowel syndrome.” Digestive Diseases and Sciences, Vol. 59, No. 6 (2014): 1278–1285.
- Rao, S.S.C., and J. Bhagatwala. “Small intestinal bacterial overgrowth: Clinical features and therapeutic management.” Clinical and Translational Gastroenterology, Vol. 10, No. 10 (2019): e00078.
- Gatta, L., and C. Scarpignato. “Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.” Alimentary Pharmacology & Therapeutics, Vol. 45, No. 5 (2017): 604–616.
- Nickles, M.A., A. Hasan, A. Shakhbazova, S. Wright, C.J. Chambers, and R.K. Sivamani. “Alternative treatment approaches to small intestinal bacterial overgrowth: A systematic review.” Journal of Alternative and Complementary Medicine, Vol. 27, No. 2 (2021): 108–119.
- Chedid, V., S. Dhalla, J.O. Clarke, B.C. Roland, K.B. Dunbar, J. Koh, E. Justino, E. Tomakin, and G.E. Mullin. “Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.” Global Advances in Health and Medicine, Vol. 3, No. 3 (2014): 16–24.
- Dinicola, S., S. De Grazia, G. Carlomagno, and J.P. Pintucci. “N‑Acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review.” European Review for Medical and Pharmacological Sciences, Vol. 18, No. 19 (2014): 2942–2948.
- Çevik, K., and S. Ulusoy. “Inhibition of Pseudomonas aeruginosa biofilm formation by 2,2′‑bipyridyl, lipoic, kojic and picolinic acids.” Iranian Journal of Basic Medical Sciences, Vol. 18, No. 8 (2015): 758–763.
- Rosania, R., F. Giorgio, M. Principi, A. Amoruso, R. Monno, A. Di Leo, and E. Ierardi. “Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation.” Current Clinical Pharmacology, Vol. 8, No. 2 (2013): 169–172.
- Lyszkowska M, Popinska K, Idzik M, Ksiazyk P. “Probiotics in children with gut failure.” J Pediatr Gastroenterol Nutr. 2008;46:543
- Pimentel, M., T. Constantino, Y. Kong, M. Bajwa, A. Rezaei, and S. Park. “A 14‑day elemental diet is highly effective in normalizing the lactulose breath test.” Digestive Diseases and Sciences, Vol. 49, No. 1 (2004): 73–77.
- Madrid, A.M., C. Hurtado, M. Venegas, F. Cumsille, and C. Defilippi. “Long-term treatment with cisapride and antibiotics in liver cirrhosis: Effect on small intestinal motility, bacterial overgrowth, and liver function.” The American Journal of Gastroenterology, Vol. 96, No. 4 (2001): 1251–1255.
- Pimentel, M., W. Morales, S. Lezcano, D. Sun‑Chuan, K. Low, and J. Yang. “Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.” Gastroenterology & Hepatology, Vol. 5, No. 6 (2009): 435–442.